Table 1. Baseline characteristics of patients and previously published resistance mutations found at EOT.
| Patient ID (age inyears, sex) | TVR dose (mg tid) | EOT resistance mutationsa | Previous Treatment Outcome | GT | Baseline HCVRNA (IU/mL) | Follow-up HCVRNA (IU/mL) | Years between baseline and follow-up |
| 1 (53, M) | 450 | V36M+R155K(75%) | NR | 1a | 1.0E+06 | 1.3E+06 | 2.0 |
| 2 (43, M) | 450 | V36M(20%),V36A(13%), R155K(16%), R155T(16%),R155I(11%), A156T(11%) | NR | 1a | 1.2E+06 | 3.2E+05 | 4.8 |
| 3 (47, M) | 450 | V36M(22%), V36A(13%), R155K(10%), R155T(18%) | N | 1a | 8.2E+06 | 6.7E+05 | 4.7 |
| 4 (52, M) | 450 | None ≥10% | NR | 1b | 2.6E+07 | 3.8E+06 | 3.4 |
| 5 (49, M) | 450 | T54A(22%), A156V(35%) | NR | 1b | 9.4E+06 | 2.2E+05 | 4.7 |
| 6 (33, M) | 450 | V36A(47%),T54A(22%), A156S(21%) | NR | 1b | 1.3E+06 | 1.5E+05 | 4.7 |
| 7b (48, F) | 750 | T54A(26%) | NR | 1b | 5.6E+06 | 3.2E+06 | 4.6 |
| 8 (50, M) | 750 | V36M(25%),V36A(16%), R155K(26%), R155T(13%), R155I (16%) | NR | 1a | 9.2E+05 | 1.2E+06 | 4.5 |
| 9 (62, M) | 1250 | V36A(35%),T54A(27%), A156T(12%) | R | 1b | 2.2E+06 | 1.9E+06 | 1.9 |
| 10 (37, M) | 1250 | V36M(13%) | R | 1a | 3.1E+05 | 3.2E+05 | 4.5 |
| 11 (46, M) | 1250 | V36M(29%), V36M+R155K(49%) | N | 1a | 6.8E+06 | 1.8E+05 | 0.8 |
| 12 (44, M) | 1250 | T54A(67%), A156V(30%) | NR | 1b | 2.9E+06 | 2.3E+06 | 3.8 |
| 13 (52, F) | 750 | R155K(22%), V36M+R155K(63%), V36M+A156T(12%) | N | 1a | 1.1E+07 | 6.1E+05 | 3.9 |
| 14 (51, M) | 750 | A156V/T(100%) | N | 1b | 4.2E+06 | 4.9E+05 | 3.8 |
| 15 (61, M) | 750 | R155K(19%), V36M+R155K(57%) | N | 1a | 3.9E+07 | 4.8E+06 | 3.8 |
a
Resistance mutations found at ≥10% of clonal population at EOT [15]. Viral variants were cloned at EOT and the proportion of resistant variants was calculated based on the total number of clones sequenced. bEnd of treatment sequence data were not available for patient 7, short-term follow-up (7 to 10 days post dosing) data are provided here. GT,genotype; F, female; M, male, NR,non-responder; N,naïve; R,relapse.